CIAM
ACRS icon

Caitong International Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Caitong International Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,292
Closed -$1.83K – 1886
2025
Q2 		$1.83K Buy
+1,292
New +$1.75K ﹤0.01% 1414

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Caitong International Asset Management's ACRS Position: Q3 2025 in Review

Caitong International Asset Management sold out of Aclaris Therapeutics (ACRS) in Q3 2025, closing a stake of 1,292 shares — an estimated $1.83K sold.

Caitong International Asset Management first reported a position in ACRS in Q2 2025 and held it in 1 quarter. The position peaked at $1.83K in Q2 2025. 103 funds tracked by Wall St. Rank hold ACRS as of Q3 2025.

  • Caitong International Asset Management reported no remaining Aclaris Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Caitong International Asset Management sold 1,292 Aclaris Therapeutics shares in Q3 2025, an estimated $1.83K.
  • Caitong International Asset Management first reported a position in Aclaris Therapeutics in Q2 2025 and held it in 1 quarter.
  • Caitong International Asset Management's Aclaris Therapeutics position peaked at $1.83K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2025.

Based on Caitong International Asset Management's 13F filing for Q3 2025, filed 19 Nov 2025.